About a year ago, UnitedHealth Group’s Optum announced its plan to acquire home care company Amedisys for approximately $3.3 billion. This all-cash transaction for $101 per share was intended to expand UnitedHealth’s considerable presence in the home care market, a space seeing increased interest from other healthcare giants, including CVS Health and Walgreens.
The deal, however, hit a regulatory snag. The U.S. Department of Justice (DOJ) has been scrutinizing the merger, and the Oregon Health Authority launched a review to determine potential harms to residents. Additionally, the DOJ has reportedly initiated an antitrust investigation into UnitedHealth Group (UHG).
In a bid to alleviate regulatory concerns, Amedisys disclosed in a recent Securities and Exchange Commission filing that both companies have entered into a purchase agreement to sell certain home health care centers to VCG Luna, an affiliate of VitalCaring Group. This divestiture is conditional upon the successful completion of their merger, which the companies expect to finalize in the second half of 2024.
Experts believe this divestiture strategy could potentially smooth the way for DOJ approval, with some, like Dr. Robert Pearl from Stanford University, suggesting that the deal will likely proceed with minimal modifications. Dr. Adam Brown and Tyler Giesting echoed this sentiment, indicating that further divestitures may be required but are likely to remain within the home health sector, where UHG and Amedisys overlap significantly.
Despite cautious optimism among industry observers, concerns about the merger’s implications persist. Dr. Adam Brown warns about the broader ramifications of UHG’s expanding dominance in the U.S. healthcare system. As the largest private health insurer and a significant player in healthcare management, UHG’s growing influence makes market competition and negotiations increasingly difficult.
Given UHG’s substantial acquisition history, totaling over $41.4 billion across 26 acquisitions, regulatory bodies are particularly vigilant. UHG’s acquisition trail includes Change Healthcare, LHC Group, and DaVita Medical Group, alongside its ownership of OptumRx and UnitedHealthcare, which controls 15.7% of the health insurance market.
The ultimate fate of the UHG-Amedisys deal remains uncertain. While the planned divestiture to VitalCaring might address some regulatory concerns, experts suggest that additional reviews and potential approvals may hinge on how effectively UHG can mitigate its perceived market dominance.
For further details on this evolving story, visit the original article at MedCity News.